Your session is about to expire
← Back to Search
Reverse Transcriptase Inhibitors for Aicardi-Goutières Syndrome (RTI in AGS Trial)
RTI in AGS Trial Summary
This trial is testing a new HIV treatment for children 2-18 years old.
RTI in AGS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRTI in AGS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RTI in AGS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 2 and 18 years old.My genetic test shows mutations in ADAR1 or IFIH1.I am willing to have repeated spinal taps and blood tests for study purposes.I can take medicine by mouth, NG tube, or G-tube.My liver tests are more than three times the normal limit.My kidneys are not working well, with a low creatinine clearance rate.My condition matches AGS symptoms but not due to ADAR1 or IFIH1 mutations.I am HIV positive.I am willing to avoid starting any immune therapies or steroids.I am older than 18 years.I have severe issues absorbing nutrients.I have hepatitis B.I weigh at least 10 kg.
- Group 1: TDF/FTC then Placebo
- Group 2: Placebo then TDF/FTC
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is this research endeavor accommodating?
"This particular trial has already ceased to accept new participants. It was first listed on December 1st 2022 and the last update was made eight days into February of 2022. If you are seeking other clinical trials, there are currently 1389 studies engaged in recruiting patients with immune disorders, as well as 93 related to Tenofovir (TDF) and Emtricitabine (FTC)."
Are there any records of past experiments related to the combination of Tenofovir (TDF) and Emtricitabine (FTC)?
"Presently, 93 clinical trials are underway around the world to study Tenofovir (TDF) and Emtricitabine (FTC), with 29 in Phase 3. Many of these experiments are being conducted from Boylston, Massachusetts; however, 1558 locations across the globe have begun their own studies on this medication combination."
Am I a suitable candidate to participate in this trial?
"This medical trial is searching for 34 participants ages 2 to 18 that present with an immunological disorder and neurological impairment. To be eligible, patients must demonstrate their willingness to participate in lumbar punctures and blood draws; abstain from immune-modulating drugs such as corticosteroids; show molecular, neuroimaging, and clinical signs of AGS (with the exception of ADAR1 or IFIH1); exhibit interferon activation based on CSF neopterin/tetrahydrobiopterin levels upon initial evaluation; weigh at least 10kgs; have no concomitant illnesses preventing safe participation"
Does this experiment allow for recruitment of senior citizens?
"To qualify for this trial, participants must be aged between 2 and 18. The clinicaltrials database hosts 392 trials targeting patients of that age range as well as 1052 studies focusing on individuals over 65 years old."
Are any new participants being sought for this research project?
"This study, which was initially posted on December 1st 2022 and last amended on February 8th 2022 is not currently enrolling participants. However, there are 1482 other trials actively recruiting subjects at this time."
To what ailments are Tenofovir (TDF) and Emtricitabine (FTC) typically prescribed?
"Tenofovir (TDF) and Emtricitabine (FTC) are frequently used to combat the effects of hiv-1. Moreover, they can be prescribed in cases of human immunodeficiency virus transmission or infection."
Share this study with friends
Copy Link
Messenger